Skip to content
FoodEdge
News

Personalised supplements: Hikma Ventures makes its first wellness deal after 20+ in healthcare

The pharma group's venture arm has put an undisclosed sum into Rem3dy Health, the UK maker of Nourished gummies, alongside an exclusive deal to sell the brand across MENA.

For Startups
AI-generated illustration of small square gummies with several coloured layers on a steel tray under a 3D printer nozzle.
Illustration: AI-generated for FoodEdge.

Hikma Ventures, the corporate venture arm of London-listed Hikma Pharmaceuticals, has made a strategic investment in Rem3dy Health, according to a Hikma press release of 11 November 2026. The amount was not disclosed. Hikma says it is the fund's first investment in health and wellness; since 2015 it has backed more than 20 healthcare companies, in areas such as digital health, diagnostics and smart inhalers.

Rem3dy, founded in 2019 by Melissa Snover and headquartered in Birmingham according to The Grocer, makes Nourished, a gummy that layers up to seven dosed active ingredients into one "stack". Its portfolio is protected by 29 patents, the release says.

The cheque comes with a commercial contract attached. Hikma and Rem3dy "have recently entered an exclusive commercial agreement" to sell Nourished across the Middle East and North Africa, starting with Saudi Arabia and the United Arab Emirates. Nutraceutical Business Review and a Hikma LinkedIn post dated 28 October 2026 say the agreement was made public in late October. Nutraceutical Business Review reports that it covers seven markets, with first launches in the UAE, Saudi Arabia and Jordan in the first quarter of 2027, using products made in the UK.

So Hikma is now shareholder and exclusive regional seller at once. Lana Ghanem, managing director of Hikma Ventures, said the deal backs businesses that "can also create strategic value across Hikma's businesses and markets".

The last priced round gives a reference point. In June 2026 Rem3dy raised £14 million (about €16.2 million) at a valuation of £84 million (about €97.3 million), The Grocer reported, from a group including Suntory, Estrella Galicia owner Hijos de Rivera, Apollo Hospitals and UPSA. The same report put 2025 revenue at £10 million (about €11.6 million), up 61%. On those figures the June round valued the company at roughly eight times trailing revenue.

What to check

  • The price of the deal. The investment amount is undisclosed. Was it priced at, above or below the £84M June valuation, and was it equity or a convertible?
  • Exclusivity terms. An exclusive MENA agreement held by a shareholder is an asset now and a constraint later. Any future buyer inherits it. Check the term, the territory list, minimum volumes and what happens on a change of control.
  • Strategic crowding. Suntory, Hijos de Rivera, Apollo, UPSA and now Hikma are now among the investors. Several strategics can help distribution; they can also block a trade sale to a rival.
  • Unit economics. Seven layers per gummy and personalisation per order are a manufacturing cost. Ask for gross margin by channel, retail against direct-to-consumer, before and after MENA launches.
  • Evidence. The case for personalisation rests on outcomes. Ask what data shows a combined stack does more for the consumer than the same actives taken separately.

Sources and reporting

  1. Hikma Pharmaceuticals: Hikma Ventures announces strategic investment in Rem3dy Health, London, 11 November 2026 (also the PDF)
  2. Nutraceutical Business Review: Hikma invests in Rem3dy Health, 11 November 2026
  3. The Grocer: Nourished owner Rem3dy Health secures £14m for expansion, 9 June 2026

Reporting note: Desk report on the Hikma release of 11 November 2026 (page and PDF), Nutraceutical Business Review coverage the same day, a Hikma LinkedIn post dated 28 October 2026, and The Grocer's report of 9 June 2026 on the earlier funding round. The investment amount was not disclosed. Pound figures from June were converted at the ECB reference rate of 9 June 2026 (€1 = £0.8634). "Roughly eight times trailing revenue" is FoodEdge arithmetic on The Grocer's £84 million valuation and £10 million 2025 revenue figures. FoodEdge has not spoken to Hikma or Rem3dy Health.

AI tools supported source research and drafting during the editorial process.

DiscussionOpenClose

More to explore

All publications